Immune checkpoint inhibitor therapy for ACTH-secreting pituitary carcinoma: a new emerging treatment?

BACKGROUND: Pituitary carcinomas are rare but aggressive and require maximally coordinated multimodal therapies. For refractory tumors, unresponsive to temozolomide (TMZ), therapeutic options are limited. Immune checkpoint inhibitors (ICI) may be considered for treatment as illustrated in the presen...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Eur J Endocrinol
Päätekijät: Sol, Bastiaan, de Filette, Jeroen M K, Awada, Gil, Raeymaeckers, Steven, Aspeslagh, Sandrine, Andreescu, C E, Neyns, Bart, Velkeniers, Brigitte
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Bioscientifica Ltd 2020
Aiheet:
Brief Report
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7707801/
https://ncbi.nlm.nih.gov/pubmed/33112279
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1530/EJE-20-0151
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia